CO106 Efficacy of FDA-Approved Disease-Modifying Therapies (DMTS) Versus Active Comparator Medications for Relapsing-Remitting Multiple Sclerosis: A Systematic Review

Abstract

Authors

M Lingohr-Smith C Deitelzweig G Lin J Lin

Full Text Cite This Article
Back to Volume 25, Supplemental Issue 7S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×